Jpmorgan Chase & CO Merrimack Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 Dec 26, 2024	BUY	$13.06 - $15.0 $153,925 - $176,790	11,786 New	11,786 $174,000
Q1 2024 May 10, 2024	BUY	$13.06 - $15.0 $65,260 - $74,955	4,997 Added 73.6%	11,786 $174,000
Q4 2023 Dec 26, 2024	BUY	$12.02 - $13.41 $81,603 - $91,040	6,789 New	6,789 $91,000
Q4 2023 Feb 12, 2024	BUY	$12.02 - $13.41 $24 - $26	2 Added 0.03%	6,789 $91,000
Q3 2023 Nov 14, 2023	SELL	$11.6 - $12.52 $18,061 - $19,493	-1,557 Reduced 18.66%	6,787 $83,000
Q2 2023 Aug 11, 2023	BUY	$12.02 - $13.07 $100,294 - $109,056	8,344 New	8,344 $102,000
Q4 2022 Feb 13, 2023	BUY	$3.68 - $12.51 $1,302 - $4,428	354 New	354 $4,000

Others Institutions Holding MACK

# of Institutions

1

Shares Held

77

Call Options Held

0

Put Options Held

0

Farther Finance Advisors, LLC San Francisco, CA

77
Shares

$1,165
0.0% of portfolio

About MERRIMACK PHARMACEUTICALS INC

Ticker MACK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,410,200
Market Cap $203M
Description
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

More about MACK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.